ENVALITH
塩野義製薬株式会社 logo

Shionogi & Co., Ltd.

4507・Prime Market・Pharmaceuticals

Official website
塩野義製薬株式会社 logo
Shionogi & Co., Ltd.4507

Business

Shionogi & Co., Ltd. is a long-established pharmaceutical company founded in 1878 that, building on over 60 years of accumulated infectious disease research, supplies innovative new drugs such as HIV treatments, antibacterial agents, and antiviral drugs to markets worldwide. It conducts research and development, manufacturing, and sales of prescription pharmaceuticals in a single segment, forming a global group comprising 39 consolidated subsidiaries, 6 affiliated companies, and 2 joint ventures. While relying on royalty income and dividends from ViiV Healthcare Ltd. as a primary revenue source, the company is advancing the expansion of Cefiderocol (Fetroja/Fetcroja) (antibacterial agent) and Ensitrelvir (Xocova) (COVID-19 treatment) into Europe and the US, and expanding into the QOL disease area through the integration of Torii Pharmaceutical and the JT Pharmaceutical Business (Transferred Pipeline/Royalties), aiming to transform from a drug-discovery pharmaceutical company into a HaaS (Healthcare as a Service) company.

Business Model

Of total revenue of ¥499,677 million, royalty income and dividends from ViiV Healthcare Ltd. account for more than half of revenue (sales attributable to ViiV Healthcare of ¥261,335 million, representing 52.3% of revenue). Adding to this the direct-sales business in Europe and the US for in-house-created products (Cefiderocol (Fetroja/Fetcroja), Ensitrelvir (Xocova), etc.), domestic prescription drug sales (a scale of ¥123.5 billion following the integration of Torii Pharmaceutical), and royalty income from the JT Pharmaceutical Business (Transferred Pipeline/Royalties), the company achieves stable growth by combining multiple revenue sources.

Company Strengths

Royalty income from ViiV Healthcare expanded 8.7% year-on-year to ¥261.3 billion, and dividend income grew 30.0% year-on-year to ¥52.4 billion. In March 2026, additional capital contributions made ViiV Healthcare an equity-method affiliate, further strengthening the revenue base. Progress in the development of the third-generation integrase inhibitor S-365598/VH4524184 also confirms medium- to long-term revenue continuity.

The company independently developed Cefiderocol (Fetroja/Fetcroja), the world's first siderophore cephalosporin antibacterial agent, and obtained approvals in the US, Europe, and China. For Ensitrelvir (Xocova), the FDA accepted the application for approval of the preventive indication (approval obtained in May 2026), and an application was also filed in Europe, advancing expanded indications. R&D expenses totaled ¥122,843 million, and the company holds a pipeline of over 30 products in the infectious disease and QOL disease areas.

In FY2025, the company executed three major investments: making Torii Pharmaceutical a consolidated subsidiary (domestic prescription drug sales up 25.0% year-on-year), the transfer of the JT Pharmaceutical Business (acquiring a small-molecule drug discovery platform, AI/quantum computing technology platform, and a promising pipeline), and the acquisition of the edaravone business (establishing a presence in the rare disease area). The absorption-type merger with Torii Pharmaceutical, scheduled for April 2027, has also been approved, substantially strengthening the domestic business foundation.

ENVALITH's Perspective

The equity attributable to owners of parent ratio fell sharply from 88.7% to 65.4% at the end of FY2026 (ending March 2026), with ¥660,000 million in short-term borrowings recorded under current liabilities. The cash flow to interest-bearing debt ratio also rose from 0.1 to 3.2. The company has continuously executed large-scale investments including Torii Pharmaceutical, JT Pharmaceutical Business (Transferred Pipeline/Royalties), and the edaravone business, and there is a risk that PMI costs and increased amortization expenses will pressure profit margins going forward. The forecast for profit before tax in FY2027 (ending March 2026) showing a 7.9% decrease year-on-year suggests the impact of rising expenses.

The structure in which royalty income from ViiV Healthcare Ltd. accounts for the majority of revenue continues, and the concentration risk—whereby the company's business trends and changes in contract terms directly affect performance—remains high. On the other hand, U.S. Radicava revenue via Mitsubishi Tanabe Pharma is growing, reaching ¥94,491 million in FY2025 (ending March 2026), and with the completion of rights transfer in April 2026, contribution to performance is expected from FY2027 (ending March 2026) onward. As an external environment factor in the rare disease field, regulatory incentives (such as orphan drug designation) could also serve as a tailwind.

For Ensitrelvir (Xocova), the application for preventive indication approval to the U.S. FDA has been accepted, and an application for approval has also been filed in Europe. Domestically, approval for post-exposure prophylaxis has been obtained, and the application for a pediatric (ages 6–11) treatment indication has also been completed. However, revenue from acute respiratory infection drugs in FY2026 (ending March 2026) decreased 34.8% year-on-year due to subdued COVID-19 epidemic activity, indicating high dependence on external factors such as infectious disease outbreak trends. The timing of global approval acquisition and the state of disease outbreaks are key variables in achieving the plan, requiring continuous monitoring of progress.

Growth Strategy

Aiming to achieve the 2030 Vision through deepening the HIV business, global expansion in infectious diseases, and M&A integration

Through additional investment, ViiV Healthcare has become an equity-method affiliate, and the company aims to increase royalty income and continue expanding dividend income through expanded sales of Dovato, Cabenuva, and Apretude. Continued growth in HIV-related royalty income is expected in FY2027 (ending March 2027) as well.

The application for approval of the preventive indication has been accepted by the US FDA, an application for approval has been filed in Europe, and approval for post-exposure prophylaxis has already been obtained domestically. The company has also filed for approval of the treatment indication for children (ages 6-11) and initiated a Phase 3 trial for ages 0-5, advancing expansion of indications and age groups.

The company is strengthening its domestic co-promotion structure through integration with Torii Pharmaceutical, and advancing the integration of the AI/quantum computing technology platform and drug discovery talent from the JT Pharmaceutical Business (Transferred Pipeline/Royalties). Torii Pharmaceutical is scheduled to be absorbed via merger in April 2027, completing the integration of the value chain.

Global transfer of all rights was completed in April 2026, and the Radicava business entity (RADIANCE NEWCO, LLC) has commenced operations. US revenue from Radicava by Mitsubishi Tanabe Pharma reached ¥94,491 million in FY2025 (ended March 2025) and continues to grow, positioning the rare disease business as a pillar of US revenue outside of infectious diseases.

The company continues to invest in its late-stage pipeline across infectious diseases, QOL diseases, and oncology, including preparations for the Phase 3 trial of the next-generation anti-coronavirus drug S-892216, initiation of a global Phase 2 trial for the Pompe disease treatment candidate S-606001, and initiation of a Phase 2 trial for the anti-CCR8 antibody S-531011.

Last updated: July 19, 2026